LifeArc Ventures
Venture arm of a medical research charity providing Seed and Series A financing plus hands-on scientific, translational and operational support to early-stage life sciences, MedTech and HealthTech companies. Offers laboratory access, translational advising, intellectual property and technology-transfer support, investor syndicate formation and commercialization advising. Portfolio companies include therapeutics and digital health ventures that have progressed assets into clinical studies and that collaborate with academic and industry partners.
Industries
Nr. of Employees
small (1-50)
LifeArc Ventures
London, England, United Kingdom, Europe
Products
Investment portfolio of early-stage life science companies
A curated portfolio of Seed and Series A companies across therapeutics, HealthTech and MedTech where LifeArc Ventures provides capital and operational/scientific support.
Investment portfolio of early-stage life science companies
A curated portfolio of Seed and Series A companies across therapeutics, HealthTech and MedTech where LifeArc Ventures provides capital and operational/scientific support.
Services
Seed and Series A investments, co-investment and follow-on financing for portfolio companies.
Access to in-house scientists and laboratory space to support early translational experiments and de-risking activities.
Support for board building, commercial strategy and introductions to industry partners and funders.
Seed and Series A investments, co-investment and follow-on financing for portfolio companies.
Access to in-house scientists and laboratory space to support early translational experiments and de-risking activities.
Support for board building, commercial strategy and introductions to industry partners and funders.
Expertise Areas
- Early-stage venture capital and syndicate management
- Translational research and preclinical development
- Biologics and antibody discovery and translation
- Digital biomarkers and at-home physiological monitoring
Key Technologies
- Monoclonal antibody discovery and development
- Engineered antibody scaffolds (antibody–miniprotein fusion approaches) for ion channel and GPCR targeting
- At-home dry electroencephalography (EEG) and wearable physiological monitoring
- Digital biomarker platforms and cloud-based multimodal analytics
News & Updates
Podcast/article feature with a senior LifeArc Ventures leader.
Overview of investments, follow-ons and portfolio progress for 2024.
Announcement that industry vaccine and infectious-disease leaders joined a portfolio company's board to support strategic, scientific and commercial direction as the company scales antibody discovery and clinical development.
Study demonstrating that repeated, self-administered dry EEG and gamified cognitive tasks at home can produce high-fidelity longitudinal data with high adherence, supporting at-home digital biomarker use in CNS research.
Series A investment to support development of engineered biologics targeting ion channels and GPCRs using an antibody-based scaffold platform.
Appointment to support scaling of a digital biomarker and physiological monitoring platform used in CNS clinical studies.
Podcast/article feature with a senior LifeArc Ventures leader.
Overview of investments, follow-ons and portfolio progress for 2024.
Announcement that industry vaccine and infectious-disease leaders joined a portfolio company's board to support strategic, scientific and commercial direction as the company scales antibody discovery and clinical development.
Study demonstrating that repeated, self-administered dry EEG and gamified cognitive tasks at home can produce high-fidelity longitudinal data with high adherence, supporting at-home digital biomarker use in CNS research.
Series A investment to support development of engineered biologics targeting ion channels and GPCRs using an antibody-based scaffold platform.
Appointment to support scaling of a digital biomarker and physiological monitoring platform used in CNS clinical studies.